Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
#What Are The Current (2025) And Forecast (2029) Sizes Of The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
The market for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer has experienced consistent growth in recent years. This market is anticipated to expand from $1.25 billion in 2024 to $1.31 billion in 2025, progressing at a compound annual growth rate (CAGR) of 4.8%. The observed growth in past periods can be attributed to several factors, including the increasing application of companion diagnostics, a heightened understanding of HER2 biomarkers among oncologists, an intensifying focus on personalized cancer treatments, a burgeoning interest in antibody-drug conjugates, and improved reimbursement policies for targeted therapies.
The market size for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is projected to experience consistent expansion over the upcoming years. By 2029, this market is anticipated to reach a valuation of $1.57 billion, exhibiting a compound annual growth rate (CAGR) of 4.6%. The expansion during the forecast period can be attributed to the expanded accessibility of molecular diagnostic laboratories, intensified awareness initiatives for gastric cancer screening, the increased adoption of next-generation sequencing (NGS), a greater need for outpatient cancer care services, and a rise in worldwide regulatory approvals for HER2 drugs. Key trends predicted for the forecast period involve optimizing treatment sequences, leveraging nanotechnology for drug delivery, applying artificial intelligence in HER2 diagnostics, improving antibody-dependent cellular cytotoxicity, and progress in combined immunotherapy approaches.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25787&type=smp
What Are The Key Drivers Of Growth In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
The increasing embrace of targeted cancer therapy is set to stimulate expansion within the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in the foreseeable future. This therapeutic approach, also referred to as personalized medicine, operates by employing specific drugs or agents to inhibit cancer growth, specifically focusing on particular molecules crucial for tumor development. Its expanding utilization stems primarily from progress in genetic profiling, which enables more exact treatments tailored to an individual’s distinct tumor characteristics, resulting in enhanced efficacy and reduced adverse effects. In the context of HER2-positive gastric cancer, targeted therapy functions by directly assailing the HER2 protein, which is found in excessive amounts in these tumors, thereby impeding disease progression and elevating patient results. A notable illustration is the February 2024 report from the Personalized Medicine Coalition, a US-based professional membership body, stating that the Food and Drug Administration (FDA) sanctioned 16 novel personalized medicines in 2023, encompassing 7 cancer drugs and 3 for other diverse conditions, marking a rise from 6 approvals in 2022. Consequently, the growing acceptance of targeted cancer therapy is serving as a key impetus for the expansion of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market.
What Are The Major Segment Types Covered In The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market covered in this report is segmented –
1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy
2) By Stage: Stage I, Stage II, Stage III, Stage IV
3) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users
Subsegments:
1) By Chemotherapy: Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines
2) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies
3) By Radiation Therapy: External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy
4) By Targeted Therapy: HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors
How Are Trends Influencing The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
Leading companies in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market are concentrating on securing regulatory approvals for novel treatments, including advanced immunotherapy-enhanced combination regimens. These regimens, which integrate immune checkpoint inhibitors with targeted therapy and chemotherapy, aim to substantially enhance patient results in initial treatment scenarios. This strategy utilizes the body’s immune defenses by blocking programmed death (PD)-1 or programmed death (PD)-L1 interaction, concurrently targeting HER2 receptors, and employing chemotherapeutic agents, thereby boosting anti-tumor efficacy and improving survival rates. As an illustration, in March 2025, the U.S. Food and Drug Administration (FDA) granted approval to Merck & Co., Inc., a US-based biopharmaceutical company, for pembrolizumab (Keytruda) in combination with trastuzumab and chemotherapy. This was sanctioned as a frontline therapy for adult patients suffering from HER2-positive unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, specifically those whose tumors exhibit programmed death (PD)-L1 expression. This recently sanctioned combination treatment exhibited significant gains in both median progression-free survival and overall survival when benchmarked against conventional regimens. Achieving a higher overall response rate of 73% and an extended median duration of response, this therapy marks a transformative change in addressing advanced HER2-positive gastric cancers.
Which Leading Companies Dominate The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Share?
Major companies operating in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.
Download The Full Report For Exclusive Market Findings:
Which Geographies Are Emerging As Strong Markets For The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Industry?
North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Report:
https://www.thebusinessresearchcompany.com/customise?id=25787&type=smp
Browse Through More Reports Similar to the Global Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market 2025, By The Business Research Company
Gastric Cancer Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report
Gastric Cancer Diagnostic Procedure Global Market Report 2025
Intestine Cancer Therapeutics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/intestine-cancer-therapeutics-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model